[Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate]
Background. Uterine leiomyoma is one of the most common benign tumors of the female genital organs. The main conservative treatment of leiomyoma is progesterone receptor blockers that suppress myoma growth and may lead to its regression. Objective. To study the immunohistochemical features of myoma...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of Ukraine. Dnipropetrovsk Medical Academy
2015-09-01
|
| Series: | Морфологія |
| Subjects: | |
| Online Access: | http://www.morphology.dp.ua/_pub/MORPHO-2015-09-03/15keglua.pdf |
| _version_ | 1828553425188552704 |
|---|---|
| author | Kuryk E.G. Litvak E.O. Chabrat B.V. Lysenko B.M. |
| author_facet | Kuryk E.G. Litvak E.O. Chabrat B.V. Lysenko B.M. |
| author_sort | Kuryk E.G. |
| collection | DOAJ |
| description | Background. Uterine leiomyoma is one of the most common benign tumors of the female genital organs. The main conservative treatment of leiomyoma is progesterone receptor blockers that suppress myoma growth and may lead to its regression. Objective. To study the immunohistochemical features of myoma tissue in patients with uterine leiomyoma after treatment with selective progesterone modulator - ulipristal acetate. Methods. Leiomyoma tissue obtained from 9 patients after ulipristal acetate treatment were investigated. Group for comparison - leiomyoma from patients without hormonal therapy. Immunohistochemical study of progesterone and estrogen receptors, proliferative activity marker Ki-67 and inhibitor of apoptosis Bcl-2 was performed. Results. In the group of patients without preoperative hormonal treatment progesterone receptors were expressed in 76,4±6,8% of the nuclei, estrogen receptors - in 32,8±2,6%. In the group of patients after treatment with ulipristal acetate there was a significant decrease of progesterone receptor expression – 36,8±1,28% (p <0,05) and a nonsignificant decrease of estrogen expression – 30,7±3,4% (p> 0,05) . Bcl-2 in the control group was found in 65,4±7,2% cells, in leiomyoma after treatment there was a significant decrease of bcl-2 – 42,6±3,2% (p <0, 05). In leiomyomas without hormonal treatment Ki-67 was determined in 11,8% of the nuclei of smooth muscle cells, and in leiomyomas after ulipristal acetate – in 7,2% leiomyoma cells. Conclusions. In patients after three months of ulipristal acetate treatment there was a significant decrease of expression of progesterone receptor, bcl-2, and Ki-67. Taken together these data evidence reduced action of progesterone on leiomyoma cells, induction of apoptosis and decreased proliferation processes that may cause involution of fibroids.
Citation:
Kuryk EG, Litvak EO, Chabrat BV, Lysenko BM. [Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate]. Morphologia. 2015;9(3):42-7. Russian |
| first_indexed | 2024-12-12T05:17:13Z |
| format | Article |
| id | doaj.art-65b6b0c1f3dd440c97a22b8386b1d48c |
| institution | Directory Open Access Journal |
| issn | 1997-9665 1997-9665 |
| language | Russian |
| last_indexed | 2024-12-12T05:17:13Z |
| publishDate | 2015-09-01 |
| publisher | Ministry of Health of Ukraine. Dnipropetrovsk Medical Academy |
| record_format | Article |
| series | Морфологія |
| spelling | doaj.art-65b6b0c1f3dd440c97a22b8386b1d48c2022-12-22T00:36:43ZrusMinistry of Health of Ukraine. Dnipropetrovsk Medical AcademyМорфологія1997-96651997-96652015-09-01934247[Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate]Kuryk E.G.0Litvak E.O.1Chabrat B.V.2Lysenko B.M.3State Scientific Institution “Scientific and Practical Center of Preventive and Clinical Medicine” of Public Administration, Kyiv, UkraineState Scientific Institution “Scientific and Practical Center of Preventive and Clinical Medicine” of Public Administration, Kyiv, UkraineState Scientific Institution “Scientific and Practical Center of Preventive and Clinical Medicine” of Public Administration, Kyiv, UkraineState Scientific Institution “Scientific and Practical Center of Preventive and Clinical Medicine” of Public Administration, Kyiv, UkraineBackground. Uterine leiomyoma is one of the most common benign tumors of the female genital organs. The main conservative treatment of leiomyoma is progesterone receptor blockers that suppress myoma growth and may lead to its regression. Objective. To study the immunohistochemical features of myoma tissue in patients with uterine leiomyoma after treatment with selective progesterone modulator - ulipristal acetate. Methods. Leiomyoma tissue obtained from 9 patients after ulipristal acetate treatment were investigated. Group for comparison - leiomyoma from patients without hormonal therapy. Immunohistochemical study of progesterone and estrogen receptors, proliferative activity marker Ki-67 and inhibitor of apoptosis Bcl-2 was performed. Results. In the group of patients without preoperative hormonal treatment progesterone receptors were expressed in 76,4±6,8% of the nuclei, estrogen receptors - in 32,8±2,6%. In the group of patients after treatment with ulipristal acetate there was a significant decrease of progesterone receptor expression – 36,8±1,28% (p <0,05) and a nonsignificant decrease of estrogen expression – 30,7±3,4% (p> 0,05) . Bcl-2 in the control group was found in 65,4±7,2% cells, in leiomyoma after treatment there was a significant decrease of bcl-2 – 42,6±3,2% (p <0, 05). In leiomyomas without hormonal treatment Ki-67 was determined in 11,8% of the nuclei of smooth muscle cells, and in leiomyomas after ulipristal acetate – in 7,2% leiomyoma cells. Conclusions. In patients after three months of ulipristal acetate treatment there was a significant decrease of expression of progesterone receptor, bcl-2, and Ki-67. Taken together these data evidence reduced action of progesterone on leiomyoma cells, induction of apoptosis and decreased proliferation processes that may cause involution of fibroids. Citation: Kuryk EG, Litvak EO, Chabrat BV, Lysenko BM. [Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate]. Morphologia. 2015;9(3):42-7. Russianhttp://www.morphology.dp.ua/_pub/MORPHO-2015-09-03/15keglua.pdfleiomyomas of the uterusprogesterone receptorsproliferationapoptosisulipristal acetate |
| spellingShingle | Kuryk E.G. Litvak E.O. Chabrat B.V. Lysenko B.M. [Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate] Морфологія leiomyomas of the uterus progesterone receptors proliferation apoptosis ulipristal acetate |
| title | [Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate] |
| title_full | [Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate] |
| title_fullStr | [Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate] |
| title_full_unstemmed | [Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate] |
| title_short | [Immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate] |
| title_sort | immunohistochemical characteristic of myoma tissue in patients with uterine leiomyoma after treatment with ulipristal acetate |
| topic | leiomyomas of the uterus progesterone receptors proliferation apoptosis ulipristal acetate |
| url | http://www.morphology.dp.ua/_pub/MORPHO-2015-09-03/15keglua.pdf |
| work_keys_str_mv | AT kurykeg immunohistochemicalcharacteristicofmyomatissueinpatientswithuterineleiomyomaaftertreatmentwithulipristalacetate AT litvakeo immunohistochemicalcharacteristicofmyomatissueinpatientswithuterineleiomyomaaftertreatmentwithulipristalacetate AT chabratbv immunohistochemicalcharacteristicofmyomatissueinpatientswithuterineleiomyomaaftertreatmentwithulipristalacetate AT lysenkobm immunohistochemicalcharacteristicofmyomatissueinpatientswithuterineleiomyomaaftertreatmentwithulipristalacetate |